Taking Stock of Hims & Hers Health (HIMS) Valuation After Recent Share Price Dip

Hims & Hers Health (HIMS) shares recently saw a modest dip of about 7% in a single trading session. This caught investors’ attention and sparked questions about what could be driving short-term moves, despite solid long-term gains.

See our latest analysis for Hims & Hers Health.

While the recent 7% dip stands out, it's a minor bump in an overall impressive run for Hims & Hers Health. The company’s share price has soared more than double year-to-date. Its total shareholder return over the past year is even more striking at nearly 189%, with a staggering 1,031% total return over three years. This is a clear sign that momentum hasn’t faded even if some volatility remains.

Curious where else investors are finding explosive growth? Now could be the perfect moment to broaden your search and discover See the full list for free.

Given the rapid rise in Hims & Hers Health’s valuation, the key question for investors is whether the stock remains undervalued with room to run, or if the market has already priced in all that future growth.

Most Popular Narrative: 37.3% Undervalued

According to the most popular narrative by BlackGoat, Hims & Hers Health's fair value stands far above the latest closing price of $53.95. This suggests major upside in the eyes of narrative backers. The stage is set for a closer look at the growth drivers powering this conviction.

Hims is demonstrating rare execution: fast growth, rising profitability, and increasing efficiency all at once. The company is not only expanding its subscriber base but also deepening engagement through personalised care, which boosts retention and monetisation.

Read the complete narrative.

Want to dig into why this price target is turning heads? There is a bold revenue ramp, margin leap, and profit surge at the core of this story. Which ambitious assumptions make up the foundation of this fair value? Crack open the full narrative to discover the numbers that could rewrite the healthcare playbook.

Result: Fair Value of $86.09 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, regulatory scrutiny or sudden changes in partnership agreements could quickly alter the growth trajectory of Hims & Hers Health and test investors’ conviction.

Find out about the key risks to this Hims & Hers Health narrative.

Another View: Price Ratios Raise Questions

Taking a look at valuation through earnings multiples tells a different story. Hims & Hers Health trades at 63 times earnings, much higher than the US Healthcare industry's average of 21.4 and the peer average of 43.9. Even compared to its fair ratio of 64.8, shares look richly priced. Does this hefty premium mean investors are overconfident about future growth?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Hims & Hers Health Narrative

If you’re looking to dig deeper or want to challenge the consensus, you can quickly build your own view using all the numbers and details at hand. Do it your way Do it your way.

A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Smart investors are always searching for promising stocks before the crowd. Use these carefully selected screens and never let a future winner pass you by.

• Unlock income opportunities by checking out these 19 dividend stocks with yields > 3%, which offers attractive yields above 3% for steady returns and reliability in uncertain markets.
• Stay ahead of the tech curve when you scan these 24 AI penny stocks, focused on artificial intelligence, where tomorrow's game-changers are making headlines today.
• Get in early on leaders transforming finance by exploring these 79 cryptocurrency and blockchain stocks to find companies shaping the future with blockchain innovation and digital assets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com